154 related articles for article (PubMed ID: 25794135)
21.
Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
24. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
25. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
26. [Clinical role of BRAF V600E mutation testing in thyroid nodules].
Wan H; Zhang B; Wang Y; Xiao T; Guo H; Liu W; Yan D; Xu Z; Tang P
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jun; 49(6):468-72. PubMed ID: 25241863
[TBL] [Abstract][Full Text] [Related]
27. Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia.
Ewalt M; Nandula S; Phillips A; Alobeid B; Murty VV; Mansukhani MM; Bhagat G
Hematol Oncol; 2012 Dec; 30(4):190-3. PubMed ID: 22246856
[TBL] [Abstract][Full Text] [Related]
28. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
29. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
30. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
31. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.
Bohn OL; Hsu K; Hyman DM; Pignataro DS; Giralt S; Teruya-Feldstein J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e65-8. PubMed ID: 24445188
[No Abstract] [Full Text] [Related]
32. New Targets and New Agents in High-Risk Multiple Myeloma.
Nooka AK; Lonial S
Am Soc Clin Oncol Educ Book; 2016; 35():e431-41. PubMed ID: 27249751
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting MEK in MAPK pathway-activated myeloma.
Heuck CJ; Jethava Y; Khan R; van Rhee F; Zangari M; Chavan S; Robbins K; Miller SE; Matin A; Mohan M; Ali SM; Stephens PJ; Ross JS; Miller VA; Davies F; Barlogie B; Morgan G
Leukemia; 2016 Apr; 30(4):976-80. PubMed ID: 26228812
[No Abstract] [Full Text] [Related]
34. Genomics of Multiple Myeloma.
Robiou du Pont S; Cleynen A; Fontan C; Attal M; Munshi N; Corre J; Avet-Loiseau H
J Clin Oncol; 2017 Mar; 35(9):963-967. PubMed ID: 28297630
[TBL] [Abstract][Full Text] [Related]
35. [Predictive molecular pathological stratification of hematological neoplasms].
Andrulis M
Pathologe; 2016 Nov; 37(Suppl 2):210-216. PubMed ID: 27613303
[TBL] [Abstract][Full Text] [Related]
36. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.
Kortuem KM; Braggio E; Bruins L; Barrio S; Shi CS; Zhu YX; Tibes R; Viswanatha D; Votruba P; Ahmann G; Fonseca R; Jedlowski P; Schlam I; Kumar S; Bergsagel PL; Stewart AK
Blood Cancer J; 2016 Feb; 6(2):e397. PubMed ID: 26918361
[TBL] [Abstract][Full Text] [Related]
37. Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.
Perrot A; Corre J; Avet-Loiseau H
Am Soc Clin Oncol Educ Book; 2018 May; 38():675-680. PubMed ID: 30231368
[TBL] [Abstract][Full Text] [Related]
38. Electron microscopic analysis of myeloma cells in relation to drug response and prognosis.
Kurabayashi H; Kubota K; Shirakura T; Tamura J; Murakami H; Naruse T; Tsuchiya J
Ultrastruct Pathol; 1992; 16(3):379-83. PubMed ID: 1585499
[TBL] [Abstract][Full Text] [Related]
39. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Ruiz-Heredia Y; Sánchez-Vega B; Onecha E; Barrio S; Alonso R; Martínez-Ávila JC; Cuenca I; Agirre X; Braggio E; Hernández MT; Martínez R; Rosiñol L; Gutierrez N; Martin-Ramos M; Ocio EM; Echeveste MA; de Oteyza JP; Oriol A; Bargay J; Gironella M; Ayala R; Bladé J; Mateos MV; Kortum KM; Stewart K; García-Sanz R; Miguel JS; Lahuerta JJ; Martinez-Lopez J
Haematologica; 2018 Nov; 103(11):e544-e548. PubMed ID: 29954938
[No Abstract] [Full Text] [Related]
40. Indication for therapy in multiple myeloma: should it be stage or stability?
Joshua DE; Wearne A; Kronenberg H
Lancet; 1985 Jul; 2(8448):210. PubMed ID: 2862389
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
